Mark Kowalski, MD PhD

Chief Medical Officer
Eupraxia Pharmaceuticals
Victoria, British Columbia, Canada

Disclosure information not submitted.

Presentation(s):

• EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate): Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in 318 Subjects with Knee Osteoarthritis

  POSTER ABSTRACT